

2020 EMERGING THERAPIES FOR PBC, NASH, ESLD AND HCC SEMINAR SERIES

Phoenix, AZ August 22, 2020

**Conference
Location**

Black Canyon Conference Center

Phone: (602) 944-0569

9440 N. 25th Avenue
Phoenix, Arizona

<http://www.blackcanyonconferencecenter.com>

**Parking at the
Conference**

Complimentary self-parking rate has been arranged for program participants

Driving Directions

The Black Canyon Conference Center is conveniently located off Highway 17, north of downtown and between Dunlap and Peoria Avenues

- Exit Highway 17 at W. Dunlap Avenue and proceed East
- Take your first left (north) on North. 25th Avenue
- The conference center will be on your left

**Seminar Agenda
and Syllabus
Information**

Registration and breakfast begin at **7:30 a.m.** in the **Joshua Tree Room**. Please check signage for any last minute room changes.

The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the *App* will be provided to participants in advance of the seminar. WiFi will be available without charge.

7:30 am	<i>Registration, Continental Breakfast & View Exhibits</i>
8:00 am	Opening Comments and Pre-Test
8:20 am	End Stage Liver Disease: Treatment, Managing Complications and Transplant <ul style="list-style-type: none"> • Staging, workup, and diagnosis of cirrhosis • Medical care of the patient with end stage liver disease Liver Transplantation <ul style="list-style-type: none"> • Listing criteria, MELD scores, Exceptions and the transplant process Case Study 1 – Cirrhosis and Encephalopathy
9:25 am	Hepatocellular Carcinoma (HCC) <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Diagnosis without histology • Treatment and management options: Ablation, TACE and Surgery
10:00 am	<i>Break & View Exhibits</i>
10:15 am	Hepatocellular Carcinoma: New Systemic Treatment Options <ul style="list-style-type: none"> • Current FDA-Approved Therapies • New chemotherapy regimens in development and testing • Immunotherapy as the new MoA for HCC Case Study 2 – Diagnosis and Treatment of Hepatocellular Carcinoma
11:00 am	Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis <ul style="list-style-type: none"> • Epidemiology of PSC and Ursodiol and Antibiotic Treatments • Predicting outcomes and Improving Survival in PSC patients • Causes and Markers of PBC • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid

11:40 am	Hepatology Update I – Viral Hepatitis <ul style="list-style-type: none"> The reemergence of Hepatitis A, Autoimmune Hepatitis and Transplanting HCV+ organs
12:00 pm	Luncheon and Educational Session. Hosted by AbbVie
12:55pm	Dessert and View Exhibits
1:10pm	Hepatology Update II - Current/Emerging Topics in Liver Disease <ul style="list-style-type: none"> Alcoholic Liver Disease, Liver Disease and Pregnancy, Hepatorenal Syndrome
1:40 pm	NAFLD, LAL-D and NASH <ul style="list-style-type: none"> Epidemiology, Demographics and Diagnosis Treatment options for thrombocytopenia; including alternatives to platelet transfusion. Treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D) causing adult Fatty Liver Disease
2:15 pm	Break & View Exhibits
2:30 pm	NASH Treatments in Practice and in Development <ul style="list-style-type: none"> Current therapies for NASH Life style changes as a therapy Drugs in clinical development for NASH Case Study 3 - NASH Diagnosis and Treatment
3:20 pm	Post-test and Wrap-Up

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is **received in writing no later than seven days prior** to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)**TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Information

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.3 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-20-1150. The Kentucky Board of Nursing approval of an individual nursing education provide does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)TM organizations accredited by ACCME.

RICHARD A. MANCH, MD, FAASLD, FACG



Dr Richard A. Manch currently serves as Chief of Hepatology at Arizona Liver Health, with research and clinic sites in Chandler, Glendale and Tucson, Arizona. He is board certified in Internal Medicine, Gastroenterology and Transplant Hepatology. A graduate of the State University of New York in Buffalo (B.A., M.D.), he also holds a master's degree in Health Administration from the University of Colorado. He is a Fellow of the American College of Physicians, the American College of Gastroenterology and the American College of Physician Executives and is Clinical Professor of Medicine with the University of Arizona and Professor of Medicine with Creighton University. Dr. Manch has been instrumental in developing two liver transplant programs in Arizona and developed an extensive network of liver disease outreach clinics throughout the state, before redirecting his efforts toward the development of innovative ways to provide specialized Hepatology consultation by teleconferencing with primary providers in medically underserved areas.

HUGO E. VARGAS, MD, MS, FACP, FAASLD



Hugo Vargas received his medical degree from Hahnemann University Graduate School of Medicine in Philadelphia, PA after graduating with a BS in Physiology from UC Davis. Concurrently, he expanded his study in Human Physiology receiving a Master's of Science degree.

Dr. Vargas is certified in Internal Medicine, Gastroenterology and Transplant Hepatology. Clinically, Dr. Vargas is interested in hepatitis, End-stage liver disease and hepatocellular carcinoma. He participates in clinical and diagnostic trials and collaborates with research partners at the Mayo Clinic and with national experts in the treatment of liver disease.

He is the recipient of many professional and academic awards including Outstanding Fellowship Director of the Year and Investigator of the Year at Mayo. Dr. Vargas is also active in AASLD and serves on their education, research and membership committees. IN 2014, he was awarded Fellowship in AASLD

ANN MOORE, FNP-C



Ann Moore has over 30 years of liver disease and complex liver transplant management experience. As a board-certified nurse practitioner, Ann is recognized nationally for her liver disease expertise, and serves as an advisor to many organizations and companies involved in the management of liver disease.

She has worked to expand access to liver disease care throughout the state of Arizona, running numerous outreach clinics in rural locations utilizing the ECHO telementoring program. She was awarded the American Academy of Nurse Practitioner State Award for Excellence in 2014 for her work with Hepatitis C patients in rural and underserved communities. Ann has also received several grants for expanding liver disease education programs and research grants for the study of hepatitis C and primary biliary cirrhosis.
